Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Next Previous
Trial Profile

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epcoritamab (Primary) ; Cyclophosphamide; Doxorubicin; Lenalidomide; Pirtobrutinib; Prednisone; Rituximab; Venetoclax; Vincristine; Vinorelbine
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms EPCORE CLL-1
  • Sponsors Genmab

Most Recent Events

  • 08 Dec 2025 According to Genmab Media Release data from the trial were presented at The Lancet Haematology.
  • 08 Dec 2025 According to Genmab Media Release data from the trial were presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH), in Orlando, Florida.
  • 08 Dec 2025 Results presented in the Genmab Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top